Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background
:
RUFY3
(RUN and FYVE domain-containing protein 3) has been shown to participate in cell migration, membrane transportation, and cellular signaling and is dysregulated in several cancer processes. However, the role of
RUFY3
in lung cancer remains unclear. In the present study, we aimed to study the expression of
RUFY3
and assess its clinical significance in lung adenocarcinoma.
Materials and Methods
: We used immunohistochemistry to detect
RUFY3
protein expression in human lung adenocarcinoma and adjacent normal lung tissue from 125 patients who underwent surgical resection of the lung cancer.
RUFY3
expression was assessed in association with clinicopathological characteristics and clinical prognosis of lung adenocarcinoma patients. The expression of
RUFY3
in three different lung adenocarcinoma cell lines and one normal lung epithelial cell (BEAS-2B) was detected by western blot. RNAi technique was used to silence
RUFY3
. We assessed cell migration by Trans-well assay and wound healing assay.
Results
: In lung adenocarcinoma tissues,
RUFY3
protein was significantly upregulated compared to paired normal lung tissues. High cytoplasmic
RUFY3
levels were associated with lymph node metastasis, TNM staging, and survival status. Patients with the highest expression level of
RUFY3
had a shorter survival time than patients with the lowest expression. Inhibition of
RUFY3
by siRNA inhibited cell migration. Furthermore, silence of
RUFY3
lead to up-regulation of E-cadherin, but down-regulation of N-cadherin, Vimentin and Slug.
Conclusions
: Our study is first to demonstrated that abnormal expression of
RUFY3
indicates poor prognosis in lung adenocarcinoma and also indicates that
RUFY3
may be related to
EMT
process. This highlights the potential of
RUFY3
as a novel prognostic biomarker for lung adenocarcinoma.
...
PMID:RUFY3 Predicts Poor Prognosis and Promotes Metastasis through Epithelial-mesenchymal Transition in Lung Adenocarcinoma. 3177 61
